


CLAIMS


1. A pyrazole derivative represented by the following general formula (I α):



wherein

R^1 represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

one of Q⁰ and T⁰ represents a group selected from



, and the other represents a group represented by the formula:

$-(CH_2)_n-Ar$ wherein Ar represents a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following

- 5 substituent group (B) or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B); and n represents an integral number from 0 to 2, a C_{1-6} alkoxy group which may have the same or different 1 to 3 groups selected from the following substituent group (A),
- 10 an optionally mono or di(C_{1-6} alkyl)-substituted amino group wherein the C_{1-6} alkyl group may have the same or different 1 to 3 groups selected from the following substituent group (A), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A),
- 15 or a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

- R represents a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following
- 20 substituent group (A), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a C_{1-9} heteroaryl group which may have
- 25 the same or different 1 to 3 groups selected from the following

substituent group (B);

[substituent group (A)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^1$, $-OG^2$, $-SG^2$, $-N(G^2)_2$, $-C(=O)G^2$, $-C(=O)OG^2$,

5 $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

[substituent group (B)]:

a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$,
10 $-SG^2$, $-N(G^2)_2$, $-G^3OG^4$, $-G^3N(G^4)_2$, $-C(=O)G^2$, $-C(=O)OG^2$, $-C(=O)N(G^2)_2$, $-S(=O)_2G^2$, $-S(=O)_2OG^2$, $-S(=O)_2N(G^2)_2$, $-S(=O)G^1$, $-OC(=O)G^1$, $-OC(=O)N(G^2)_2$, $-NHC(=O)G^2$, $-OS(=O)_2G^1$, $-NHS(=O)_2G^1$ and $-C(=O)NHS(=O)_2G^1$;

in the above substituent group (A) and/or (B),

15 G^1 represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkynyl group which may have the same or different 1 to
20 3 groups selected from the following substituent group (C), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a
25 C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C_{1-9} heteroaryl group which may have the same or different

1 to 3 groups selected from the following substituent group (D);

G^2 represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), and with the proviso that G^2 may be the same or different when there are 2 or more G^2 in the substituents;

G^3 represents a C_{1-6} alkyl group;

G^4 represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), and with the proviso that G^4 may be the same or different when there are 2 or more G^4 in the substituents;

[substituent group (C)]:

a halogen atom, a nitro group, a cyano group, an oxo group,
 $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$,
 $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$,
 $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and

$-\text{C}(=\text{O})\text{NHS}(=\text{O})_2\text{G}^5$; and


[substituent group (D)]:

a halogen atom, a nitro group, a cyano group, $-\text{G}^5$, $-\text{OG}^6$, $-\text{SG}^6$, $-\text{N}(\text{G}^6)_2$, $-\text{C}(=\text{O})\text{G}^6$, $-\text{C}(=\text{O})\text{OG}^6$, $-\text{C}(=\text{O})\text{N}(\text{G}^6)_2$, $-\text{S}(=\text{O})_2\text{G}^6$,
 5 $-\text{S}(=\text{O})_2\text{OG}^6$, $-\text{S}(=\text{O})_2\text{N}(\text{G}^6)_2$, $-\text{S}(=\text{O})\text{G}^5$, $-\text{OC}(=\text{O})\text{G}^5$, $-\text{OC}(=\text{O})\text{N}(\text{G}^6)_2$,
 $-\text{NHC}(=\text{O})\text{G}^6$, $-\text{OS}(=\text{O})_2\text{G}^5$, $-\text{NHS}(=\text{O})_2\text{G}^5$ and $-\text{C}(=\text{O})\text{NHS}(=\text{O})_2\text{G}^5$;
 in the substituent group (C) and/or (D),

G^5 represents a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a
 10 C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group; and


G^6 represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6} alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group, and with the proviso that G^6 may be the same or different
 15 when there are 2 or more G^6 in the substituents, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

2. A pyrazole derivative as claimed in claim 1, wherein
 R^1 represents a hydrogen atom, a C_{1-6} alkyl group which may have
 20 the same or different 1 to 3 groups selected from the substituent group (A), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the substituent group (A), or a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B); Q^0 represents
 25 a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B); T^0 represents a group:



; R represents a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B); substituent group (A) consists of a halogen atom, -OG², -SG²,
 5 -N(G²)₂, -C(=O)OG², -C(=O)N(G²)₂, -S(=O)₂OG² and -S(=O)₂N(G²)₂ in which G² represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (C); or a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the substituent
 10 group (D); and substituent group (B) consists of a halogen atom, a nitro group, a cyano group, -G¹, -OG², -SG², -C(=O)OG² in which G¹ represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (C) or a C₆₋₁₀ aryl group which may have the same or different 1
 15 to 3 groups selected from the substituent group (D); and G² has the same meaning as defined above, or a pharmaceutically acceptable salt thereof or a prodrug thereof.


3. A pyrazole derivative as claimed in claim 1, wherein one
 20 of Q⁰ and T⁰ represents a group selected from



, and the other represents a group represented by the formula:

$-(CH_2)_n-Ar$, or a pharmaceutically acceptable salt thereof or a prodrug thereof.


4. A pyrazole derivative as claimed in claim 3, wherein
 5 wherein Q^0 represents a C_6-10 aryl group which may have the same or different 1 to 3 groups selected from the substituent group (B); T^0 represents a group selected from



, and R represents a C_6-10 aryl group which may have the same
 10 or different 1 to 3 groups selected from the substituent group (B), or a pharmaceutically acceptable salt thereof or a prodrug thereof.

5. A pyrazole derivative as claimed in claim 4, wherein


15 T^0 represents a group:



; and substituent group (B) consists of a halogen atom, a nitro group, a cyano group, $-G^1$, $-OG^2$, $-SG^2$ and $-C(=O)OG^2$ in which G^1 represents a C_1-6 alkyl group which may have the same or
 20 different 1 to 3 groups selected from the substituent group (C) or a C_6-10 aryl group which may have the same or different 1 to 3 groups selected from the substituent group (D); and G^2


represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the substituent group (C) or a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the substituent group (D), or a
 5 pharmaceutically acceptable salt thereof or a prodrug thereof.

6. A pyrazole derivative as claimed in claim 1, wherein one of Q⁰ and T⁰ represents a group selected from




10 , and the other represents a C₁₋₆ alkoxy group which may have the same or different 1 to 3 groups selected from the substituent group (A), an optionally mono or di(C₁₋₆ alkyl)-substituted amino group in which the C₁₋₆ alkyl group may have the same or different 1 to 3 groups selected from the substituent group (A), or a C₂₋₉
 15 heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the substituent group (A), or a pharmaceutically acceptable salt thereof or a prodrug thereof.

7. A pyrazole derivative as claimed in claim 6, wherein Q⁰
 20 represents an optionally mono or di(C₁₋₆ alkyl)-substituted amino group in which the C₁₋₆ alkyl group may have the same or different 1 to 3 groups selected from the substituent group (A), or a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the substituent group (A);
 25 and T⁰ represents a group selected from




, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

- 5 8. A pyrazole derivative as claimed in claim 1, wherein one of Q^0 and T^0 represents a group selected from



, and the other represents a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the
10 substituent group (B), or a pharmaceutically acceptable salt thereof or a prodrug thereof.

9. A pyrazole derivative as claimed in claim 8, wherein Q^0 represents a heterocycle-fused phenyl group which may have the
15 same or different 1 to 3 groups selected from the substituent group (B); and T^0 represents a group selected from




, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

10. A pharmaceutical composition comprising as an active

ingredient a pyrazole derivative as claimed in any one of claims 1-9, or a pharmaceutically acceptable salt thereof or a prodrug thereof.


- 5 11. An inhibitor of 1,5-anhydroglucitol/fructose/mannose transporter comprising as an active ingredient a pyrazole derivative represented by the following general formula (I):



wherein

- 10 R^1 represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C_{2-6} alkynyl group which may have the
- 15 same or different 1 to 3 groups selected from the following substituent group (A), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following
- 20 substituent group (B), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

one of Q and T represents a group selected from



, and the other represents a group represented by the formula:

$-(CH_2)_n-Ar$ wherein Ar represents a C_{6-10} aryl group which may

5 have the same or different 1 to 3 groups selected from the following
 substituent group (B) or a C_{1-9} heteroaryl group which may have
 the same or different 1 to 3 groups selected from the following
 substituent group (B); and n represents an integral number from
 0 to 2, a C_{1-6} alkyl group which may have the same or different
 10 1 to 3 groups selected from the following substituent group (A),
 a C_{1-6} alkoxy group which may have the same or different 1 to
 3 groups selected from the following substituent group (A), an
 optionally mono or di(C_{1-6} alkyl)-substituted amino group
 wherein the C_{1-6} alkyl group may have the same or different 1
 15 to 3 groups selected from the following substituent group (A),
 a C_{3-8} cycloalkyl group which may have the same or different
 1 to 3 groups selected from the following substituent group (A),
 a C_{2-9} heterocycloalkyl group which may have the same or different
 1 to 3 groups selected from the following substituent group (A),
 20 or a heterocycle-fused phenyl group which may have the same or
 different 1 to 3 groups selected from the following substituent
 group (B);

R represents a C_{3-8} cycloalkyl group which may have the
 same or different 1 to 3 groups selected from the following
 25 substituent group (A), a C_{6-10} aryl group which may have the

same or different 1 to 3 groups selected from the following substituent group (B), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B);

[substituent group (A)]:

a halogen atom, a nitro group, a cyano group, an oxo group, -G¹, -OG², -SG², -N(G²)₂, -C(=O)G², -C(=O)OG²,
 10 -C(=O)N(G²)₂, -S(=O)₂G², -S(=O)₂OG², -S(=O)₂N(G²)₂, -S(=O)G¹,
 -OC(=O)G¹, -OC(=O)N(G²)₂, -NHC(=O)G², -OS(=O)₂G¹, -NHS(=O)₂G¹
 and -C(=O)NHS(=O)₂G¹;

[substituent group (B)]:

a halogen atom, a nitro group, a cyano group, -G¹, -OG²,
 15 -SG², -N(G²)₂, -G³OG⁴, -G³N(G⁴)₂, -C(=O)G², -C(=O)OG²,
 -C(=O)N(G²)₂, -S(=O)₂G², -S(=O)₂OG², -S(=O)₂N(G²)₂, -S(=O)G¹,
 -OC(=O)G¹, -OC(=O)N(G²)₂, -NHC(=O)G², -OS(=O)₂G¹, -NHS(=O)₂G¹
 and -C(=O)NHS(=O)₂G¹;

in the above substituent group (A) and/or (B),

20 G¹ represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkynyl group which may have the same or different 1 to
 25 3 groups selected from the following substituent group (C), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C),

a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C),
 5 or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D);

G^2 represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkenyl group which may
 10 have the same or different 1 to 3 groups selected from the following substituent group (C), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following
 15 substituent group (C), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C), or a C₁₋₉ heteroaryl group which may have
 20 the same or different 1 to 3 groups selected from the following substituent group (D), and with the proviso that G^2 may be the same or different when there are 2 or more G^2 in the substituents;

G^3 represents a C₁₋₆ alkyl group;

G^4 represents a C₁₋₆ alkyl group which may have the same
 25 or different 1 to 3 groups selected from the following substituent group (C), and with the proviso that G^4 may be the same or different when there are 2 or more G^4 in the substituents;

[substituent group (C)]:

a halogen atom, a nitro group, a cyano group, an oxo group,
 $-G^5$, $-OG^6$, $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$,
 $-S(=O)_2G^6$, $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$,
 5 $-OC(=O)N(G^6)_2$, $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and
 $-C(=O)NHS(=O)_2G^5$; and

[substituent group (D)]:

a halogen atom, a nitro group, a cyano group, $-G^5$, $-OG^6$,
 $-SG^6$, $-N(G^6)_2$, $-C(=O)G^6$, $-C(=O)OG^6$, $-C(=O)N(G^6)_2$, $-S(=O)_2G^6$,
 10 $-S(=O)_2OG^6$, $-S(=O)_2N(G^6)_2$, $-S(=O)G^5$, $-OC(=O)G^5$, $-OC(=O)N(G^6)_2$,
 $-NHC(=O)G^6$, $-OS(=O)_2G^5$, $-NHS(=O)_2G^5$ and $-C(=O)NHS(=O)_2G^5$;
 in the substituent group (C) and/or (D),

G^5 represents a C_{1-6} alkyl group, a C_{2-6} alkenyl group,
 a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10} aryl group, a
 15 C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl group; and

G^6 represents a hydrogen atom, a C_{1-6} alkyl group, a C_{2-6}
 alkenyl group, a C_{2-6} alkynyl, a C_{3-8} cycloalkyl group, a C_{6-10}
 aryl group, a C_{2-9} heterocycloalkyl group or a C_{1-9} heteroaryl
 group, and with the proviso that G^6 may be the same or different
 20 when there are 2 or more G^6 in the substituents, or a
 pharmaceutically acceptable salt thereof or a prodrug thereof.

12. An inhibitor of 1,5-anhydroglucitol/fructose/mannose
 transporter comprising as an active ingredient a pyrazole
 25 derivative as claimed in any one of claims 1-9, or a
 pharmaceutically acceptable salt thereof or a prodrug thereof.

13. An agent as claimed in claim 11, which is an agent for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose.

5

14. An agent for the prevention, inhibition of progression or treatment of a disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose comprising as an active ingredient a pyrazole derivative as claimed in any one of claims 1-9, or a pharmaceutically acceptable salt thereof or a prodrug thereof.

10

15. An agent as claimed in claim 13, wherein the disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose is diabetic complications.

15

16. An agent as claimed in claim 14, wherein the disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose is diabetic complications.

20

17. An agent as claimed in claim 15, wherein the diabetic complications is diabetic nephropathy.

25

18. An agent as claimed in claim 16, wherein the diabetic complications is diabetic nephropathy.

19. An agent as claimed in claim 13, wherein the disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose is diabetes.


20. An agent as claimed in claim 14, wherein the disease associated with the excess uptake of at least a kind of carbohydrates selected from glucose, fructose and mannose is diabetes.

21. A pharmaceutical combination which comprises (component a) a pyrazole derivative as claimed in any one of claims 1-9, or a pharmaceutically acceptable salt thereof or a prodrug thereof, and (component b) at least one member selected from the group consisting of an insulin sensitivity enhancer, a glucose absorption inhibitor, a biguanide, an insulin secretion enhancer, a SGLT2 inhibitor, an insulin or insulin analogue, a glucagon receptor antagonist, an insulin receptor kinase stimulant, a tripeptidyl peptidase II inhibitor, a dipeptidyl peptidase IV inhibitor, a protein tyrosine phosphatase-1B inhibitor, a glycogen phosphorylase inhibitor, a glucose-6-phosphatase inhibitor, a fructose-bisphosphatase inhibitor, a pyruvate dehydrogenase inhibitor, a hepatic gluconeogenesis inhibitor, D-chiroinsitol, a glycogen synthase kinase-3 inhibitor, glucagon-like peptide-1, a glucagon-like peptide-1 analogue, a glucagon-like peptide-1 agonist, amylin,

an amylin analogue, an amylin agonist, an aldose reductase inhibitor, an advanced glycation endproducts formation inhibitor, a protein kinase C inhibitor, a γ -aminobutyric acid receptor antagonist, a sodium channel antagonist, a transcript
 5 factor NF- κ B inhibitor, a lipid peroxidase inhibitor, an *N*-acetylated- α -linked-acid-dipeptidase inhibitor, insulin-like growth factor-I, platelet-derived growth factor, a platelet-derived growth factor analogue, epidermal growth factor, nerve growth factor, a carnitine derivative, uridine,
 10 5-hydroxy-1-methylhydantoin, EGB-761, bimoclomol, sulodexide, Y-128, a hydroxymethylglutaryl coenzyme A reductase inhibitor, a fibric acid derivative, a β_3 -adrenoceptor agonist, an acyl-coenzyme A cholesterol acyltransferase inhibitor, probcol, a thyroid hormone receptor agonist, a cholesterol absorption
 15 inhibitor, a lipase inhibitor, a microsomal triglyceride transfer protein inhibitor, a lipoxygenase inhibitor, a carnitine palmitoyl-transferase inhibitor, a squalene synthase inhibitor, a low-density lipoprotein receptor enhancer, a nicotinic acid derivative, a bile acid sequestrant, a sodium/bile
 20 acid cotransporter inhibitor, a cholesterol ester transfer protein inhibitor, an appetite suppressant, an angiotensin-converting enzyme inhibitor, a neutral endopeptidase inhibitor, an angiotensin II receptor antagonist, an endothelin-converting enzyme inhibitor, an endothelin receptor antagonist, a diuretic
 25 agent, a calcium antagonist, a vasodilating antihypertensive agent, a sympathetic blocking agent, a centrally acting antihypertensive agent, an α_2 -adrenoceptor agonist, an

antiplatelets agent, a uric acid synthesis inhibitor, a uricosuric agent and a urinary alkalinizer.


22. A pyrazole derivative represented by the following general
5 formula (II α):



wherein

R^{1A} represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

one of Q^{A0} and T^{A0} represents a group selected from



having protective group(s), and the other represents a group represented by the formula: $-(CH_2)_n-Ar^A$ wherein Ar^A represents a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1) or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1); and n represents an integral number from 0 to 2, a C_{1-6} alkoxy group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), an optionally mono or di(C_{1-6} alkyl)-substituted amino group wherein the C_{1-6} alkyl group may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

R^A represents a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C_{1-9} heteroaryl group which may have the same or different 1 to 3 groups selected from the following

substituent group (B1);

[substituent group (A1)]:

a halogen atom, a nitro group, a cyano group, an oxo group, $-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$,

5 $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$,
 $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$,
 $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

[substituent group (B1)]:

10 a halogen atom, a nitro group, a cyano group, $-G^{1A}$, $-OG^{2B}$,
 $-SG^{2B}$, $-N(G^{2B})_2$, $-G^3OG^{4A}$, $-G^3N(G^{4A})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$,
 $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$,
 $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$,
 $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

in the above substituent group (A1) and/or (B1),

15 G^{1A} represents a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1),
 20
 25 a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C_{1-9} heteroaryl group which may have the same or different

1 to 3 groups selected from the following substituent group (D1);

G^{2A} represents a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkenyl group which
5 may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from the
10 following substituent group (C1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C_{2-9} heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C_{1-9} heteroaryl group which may
15 have the same or different 1 to 3 groups selected from the following substituent group (D1);

G^{2B} represents a protective group, a hydrogen atom, a C_{1-6} alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkenyl
20 group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{2-6} alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C_{3-8} cycloalkyl group which may have the same or different 1 to 3 groups selected from
25 the following substituent group (C1), a C_{6-10} aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C_{2-9} heterocycloalkyl group

which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), and with the proviso that

5 G^{2B} may be the same or different when there are 2 or more G^{2B} in the substituents;

G³ represents a C₁₋₆ alkyl group;

G^{4A} represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent

10 group (C1), and with the proviso that G^{4A} may be the same or different when there are 2 or more G^{4A} in the substituents; [substituent group (C1)]:

a halogen atom, a nitro group, a cyano group, -G⁵, -OG^{6A}, -SG^{6A}, -N(G^{6A})₂, -C(=O)G⁶, -C(=O)OG^{6A}, -C(=O)N(G^{6A})₂, -S(=O)₂G⁶,
 15 -S(=O)₂OG⁶, -S(=O)₂N(G^{6A})₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G^{6A})₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵; and [substituent group (D1)]:

a halogen atom, a nitro group, a cyano group, -G⁵, -OG^{6A}, -SG^{6A}, -N(G^{6A})₂, -C(=O)G⁶, -C(=O)OG^{6A}, -C(=O)N(G^{6A})₂, -S(=O)₂G⁶,
 20 -S(=O)₂OG⁶, -S(=O)₂N(G^{6A})₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G^{6A})₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵; in the substituent group (C1) and/or (D1),


G⁵ represents a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a
 25 C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group;

G⁶ represents a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀

aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group; and

G^{6A} represents a protective group, a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group, and with the proviso that G^{6A} may be the same or different when there are 2 or more G^{6A} in the substituents, or a pharmaceutically acceptable salt thereof.

23. A pyrazole derivative represented by the following general formula (III α):



wherein

R^{1A} represents a hydrogen atom, a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C₂₋₉ heterocycloalkyl group which may

have the same or different 1 to 3 groups selected from the following substituent group (A1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

5 one of Q^{B0} and T^{B0} represents a hydroxy group, and the other represents a group represented by the formula: $-(CH_2)_n-Ar^A$ wherein Ar^A represents a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1) or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1); and n represents an integral number from 0 to 2, a C₁₋₆ alkoxy group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), an optionally mono or di(C₁₋₆ alkyl)-substituted amino group 10 wherein the C₁₋₆ alkyl group may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), or a heterocycle-fused phenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1); 20

 R^A represents a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (A1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following 25

substituent group (A1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (B1);

[substituent group (A1)]:

- 5 a halogen atom, a nitro group, a cyano group, an oxo group, $-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$, $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$, $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;

- 10 [substituent group (B1)]:

- a halogen atom, a nitro group, a cyano group, $-G^{1A}$, $-OG^{2B}$, $-SG^{2B}$, $-N(G^{2B})_2$, $-G^3OG^{4A}$, $-G^3N(G^{4A})_2$, $-C(=O)G^{2A}$, $-C(=O)OG^{2B}$, $-C(=O)N(G^{2B})_2$, $-S(=O)_2G^{2A}$, $-S(=O)_2OG^{2A}$, $-S(=O)_2N(G^{2B})_2$, $-S(=O)G^{1A}$, $-OC(=O)G^{1A}$, $-OC(=O)N(G^{2B})_2$, $-NHC(=O)G^{2A}$, $-OS(=O)_2G^{1A}$, $-NHS(=O)_2G^{1A}$ and $-C(=O)NHS(=O)_2G^{1A}$;
- 15

in the above substituent group (A1) and/or (B1),

- G^{1A} represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkenyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₂₋₆ alkynyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₃₋₈ cycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), a C₆₋₁₀ aryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different
- 20
- 25

1 to 3 groups selected from the following substituent group (C1),
or a C₁₋₉ heteroaryl group which may have the same or different
1 to 3 groups selected from the following substituent group (D1);

G^{2A} represents a hydrogen atom, a C₁₋₆ alkyl group which
5 may have the same or different 1 to 3 groups selected from the
following substituent group (C1), a C₂₋₆ alkenyl group which
may have the same or different 1 to 3 groups selected from the
following substituent group (C1), a C₂₋₆ alkynyl group which
may have the same or different 1 to 3 groups selected from the
10 following substituent group (C1), a C₃₋₈ cycloalkyl group which
may have the same or different 1 to 3 groups selected from the
following substituent group (C1), a C₆₋₁₀ aryl group which may
have the same or different 1 to 3 groups selected from the following
substituent group (D1), a C₂₋₉ heterocycloalkyl group which may
15 have the same or different 1 to 3 groups selected from the following
substituent group (C1), or a C₁₋₉ heteroaryl group which may
have the same or different 1 to 3 groups selected from the following
substituent group (D1);

G^{2B} represents a protective group, a hydrogen atom, a C₁₋₆
20 alkyl group which may have the same or different 1 to 3 groups
selected from the following substituent group (C1), a C₂₋₆ alkenyl
group which may have the same or different 1 to 3 groups selected
from the following substituent group (C1), a C₂₋₆ alkynyl group
which may have the same or different 1 to 3 groups selected from
25 the following substituent group (C1), a C₃₋₈ cycloalkyl group
which may have the same or different 1 to 3 groups selected from
the following substituent group (C1), a C₆₋₁₀ aryl group which

may have the same or different 1 to 3 groups selected from the following substituent group (D1), a C₂₋₉ heterocycloalkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), or a C₁₋₉ heteroaryl group which may have the same or different 1 to 3 groups selected from the following substituent group (D1), and with the proviso that G^{2B} may be the same or different when there are 2 or more G^{2B} in the substituents;

G³ represents a C₁₋₆ alkyl group;

10 G^{4A} represents a C₁₋₆ alkyl group which may have the same or different 1 to 3 groups selected from the following substituent group (C1), and with the proviso that G^{4A} may be the same or different when there are 2 or more G^{4A} in the substituents; [substituent group (C1)]:

15 a halogen atom, a nitro group, a cyano group, an oxo group, -G⁵, -OG^{6A}, -SG^{6A}, -N(G^{6A})₂, -C(=O)G⁶, -C(=O)OG^{6A}, -C(=O)N(G^{6A})₂, -S(=O)₂G⁶, -S(=O)₂OG⁶, -S(=O)₂N(G^{6A})₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G^{6A})₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵; and

20 [substituent group (D1)]:

a halogen atom, a nitro group, a cyano group, -G⁵, -OG^{6A}, -SG^{6A}, -N(G^{6A})₂, -C(=O)G⁶, -C(=O)OG^{6A}, -C(=O)N(G^{6A})₂, -S(=O)₂G⁶, -S(=O)₂OG⁶, -S(=O)₂N(G^{6A})₂, -S(=O)G⁵, -OC(=O)G⁵, -OC(=O)N(G^{6A})₂, -NHC(=O)G⁶, -OS(=O)₂G⁵, -NHS(=O)₂G⁵ and -C(=O)NHS(=O)₂G⁵;

25 in the substituent group (C1) and/or (D1),

G⁵ represents a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a

C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group;

G⁶ represents a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group; and

G^{6A} represents a protective group, a hydrogen atom, a C₁₋₆ alkyl group, a C₂₋₆ alkenyl group, a C₂₋₆ alkynyl, a C₃₋₈ cycloalkyl group, a C₆₋₁₀ aryl group, a C₂₋₉ heterocycloalkyl group or a C₁₋₉ heteroaryl group, and with the proviso that G^{6A} may be the same or different when there are 2 or more G^{6A} in the substituents, or a pharmaceutically acceptable salt thereof.